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Paper-based and electronic assessment of health-related quality of life 
specific to HIV disease: A reliability study with the PROQOL-HIV questionnaire
Electronic Patient Reported Outcomes (PRO) measurement provides a quick and reliable assessment of patients’ health-related 
quality of life (HRQL). It is, however, important to demonstrate the equivalence of measures derived from electronic and paper-based 
versions of a given questionnaire [1,2]. An electronic version of the PROQOL-HIV questionnaire [3,4], a 43-item questionnaire 
measuring health-related quality of life in HIV patients, was developed and its face validity and reliability was assessed using 
standard psychometric methods.
A total of 80 French outpatients (63% males, mean age 47 years) was recruited 
for this validation study (Table 1). Hard copy and electronic questionnaires were 
completed in a randomized cross-over design with a 2-7 day interval between 
completing the hard copy and the electronic versions . Biomedical and 
demographic data were collected on a separate questionnaire. Questionnaire 
version and order effects were tested on full scale scores in a two-way ANOVA 
with patients as random effects. Test-retest reliability was evaluated using 
Pearson correlation and intra-class correlation coefficients (with 95% confidence 
interval) for each dimension. Usability testing was carried out from patients’ 
survey reports, specifically: general satisfaction, ease of completion, quality and 
clarity of user interface (UI) and self motivation for electronic measuring to 
monitor HRQL in clinical follow-up.
Questionnaire version (paper/electronic) and administration order effects (N=58 complete cases) were not significant at the 5% 
level, nor interacting together (p=0.940). Reliability indices were acceptable, with Pearson correlation above 0.7 and intra-class 
correlations ranging from 0.696 [0.400;0.999] for treatment impact to 0.926 [0.886;0.973] for physical state and symptoms (Table 2 
and Figure 1). Mean scores for each dimension were not significantly different (Wilcoxon-Mann-Whitney tests, corrected for 
multiple testing), confirming scores stability across the two administrations. No adverse events were reported during the study. On 
77% of complete surveys, 57% of patients reported being satisfied and interested in electronic assessment of their HRQL in clinical 
follow up. Individual ratings of PROQOL-HIV user interface (85 to 100% of positive responses) confirmed UI clarity and usability 
(Table 3).
The electronic PROQOL-HIV introduces minor modifications compared to 
the original paper-based version and scores attained from hard copy and 
electronic version share comparable accuracy and interpretation. The ease 
in completing an electronic questionnaire and direct visual feedback to 
patients of their HRQL scores is of interest in a clinical trial setting as well 
as self- monitoring and clinical practice.
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Table 2: Reliability Analysis.
Scale scores are summarized as mean (SD) and [inter-quartile range]. Correlation measures 
stand for Bravais-Pearson linear correlation (r) and Spearman rank correlation (ρ). Results 
from Wilcoxon signed rank test for paired samples are given in the last column. * Full-scale 
score was caclulated following exclusion of 4 extra items and the GH item.
No. items Paper Electronic r (ρ) ICC (95% CI) Wilcoxon V
All items* 38 68.3 (16.5) [54.1–82.1] 69.5 (16.2) [56.7–84.4] 0.868 (0.851) 0.868 (0.815;0.931) P=0.208
BC 4 78.0 (26.1) [54.7–100.0] 76.9 (26.0) [56.2–100.0] 0.827 (0.777) 0.827 (0.708;0.955) P=0.304
ED 4 68.8 (26.9) [50.0–93.8] 69.4 (26.0) [50.0–93.8] 0.842 (0.874) 0.842 (0.772;0.929) P=0.966
GH 1 23.5 (20.7) [0.0–25.0] 21.4 (21.7) [0.0–25.0] 0.715 (0.790) 0.714 (0.550;0.881) P=0.457
HC 4 51.6 (28.3) [25.0–81.2] 55.6 (29.4) [31.2–81.2] 0.785 (0.767) 0.785 (0.680;0.884) P=0.457
IR 3 57.4 (33.8) [33.3–85.4] 63.4 (31.1) [39.6–91.7] 0.782 (0.782) 0.779 (0.625;0.909) P=0.054
PHS 9 76.3 (20.8) [63.9–94.4] 75.6 (20.3) [63.9–91.7] 0.940 (0.923) 0.939 (0.905;0.979) P=0.629
SR 2 80.8 (27.1) [75.0–100.0] 80.4 (28.9) [62.5–100.0] 0.824 (0.803) 0.822 (0.725;0.941) P=0.987
ST 2 33.3 (33.8) [0.0–50.0] 36.4 (34.5) [0.0–50.0] 0.712 (0.741) 0.712 (0.543;0.893) P=0.249
TI 10 71.7 (21.2) [57.5–90.0] 72.2 (20.9) [61.2–90.0] 0.708 (0.783) 0.708 (0.444;0.982) P=0.939
Figure 1: Distribution of participants scores.
Individual scores on electronic and paper versions of the 
PROQOL-HIV questionnaire. Individual points are diplayed with 
alpha transparency where darker symbols indicate a higher 
number of identical pairs of scores. A regression line was 
superimposed for each panel.
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Question N % (n) Mean (SD) [IQR]
Display on screen is comprehensible and easy to follow 63 100 (63)
Font size looks appropriate 62 98 (61)
Single page design is satisfactory 62 100 (62)
Visualization of results is an interesting option 61 95 (58)
Display of results is comprehensible 60 80 (48)
Ease of input responses 63 4.6 (0.7) [4–5]
Questions readability 63 4.6 (0.8) [4–5]
Scores readability 61 4 (1) [4–5]
Interested in longitudinal followup of personal scores 60 4.4 (0.9) [4–5]
Difficulty with computing material 60 13 (8)
Ease of filling (electornic vs. paper) 55 4 (1) [3–5]
Preference 55
indifferent 36 (20)
paper 9 (5)
electronic 55 (30)
Table 3: Participants 
survey responses.
N Centre 1 Centre 2 Combined
Age (years) 79 46.9 (11.2) [39.5–53.0] 44.4 (8.9) [37.0–51.0] 46.7 (10.9) [39.0–53.0] P=0.580
Gender 79 63% (44) 89% (8) 66% (52) P=0.120
No professional activity 78 21% (15) 75% (6) 27% (21) P=0.005
Level of education (university) 78 41% (29) 50% (4) 42% (33) P=0.931
Single 77 48% (33) 62% (5) 49% (38) P=0.680
Living alone 78 44% (31) 100% (8) 50% (39) P=0.009
Depression 78 13% (9) 38% (3) 15% (12) P=0.067
Psychiatric disorder 78 1% (1) 0% (0) 1% (1) P=0.730
Cardiovascular disease 78 13% (9) 38% (3) 15% (12) P=0.067
Diabete 78 9% (6) 12% (1) 9% (7) P=0.710
Other comorbidities 78 7% (5) 0% (0) 6% (5) P=0.430
Lipodystrophy 79 21% (15) 22% (2) 22% (17) P=0.960
Current treatment 78
Tuberculosis 0% (0) 0% (0) 0% (0) –––
Prophylaxis 4% (3) 38% (3) 8% (6) P<0.001
Antidepressant 11% (8) 38% (3) 14% (11) P=0.045
Lipid-lowering 10% (7) 0% (0) 9% (7) P=0.350
Year of diagnostic 79 1998 (8) [1990–2005] 2002 (7) [2000–2008] 1999 (8) [1991–2006] P=0.190
CDC Stage 79
A 59% (41) 22% (2) 54% (43) P=0.074
B 19% (13) 22% (2) 19% (15)
C 23% (16) 56% (5) 27% (21)
Year of first HAART 66 2002 (6) [1996–2007] 2008 (3) [2007–2009] 2003 (6) [1997–2007] P=0.024
Hepatitis C 79 20% (14) 0% (0) 18% (14) P=0.310
Hepatitis B 79 6% (4) 10% (1) 6% (5) P=1
CD4 counts (cell/mm3) 79 623 (438) [441–700] 407 (191) [213–527] 598 (422) [424–694] P=0.044
CD4 % 74 30.3 (10.2) [24–37] 20.2 (9.8) [19–24] 29.6 (10.4) [23–37] –––
Table 1: Demographics
Demographic and biomedical informations on study participants. For 
numerical variables, mean (SD) and inter-quartile range are provided, while 
for categorical variables reported numbers correspond to frequencies 
(counts). The number of complete cases for each variable is reported as N.
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